Using ctDNA blood tests to predict lung cancer return after surgery
Part of Cancer, Lungs & breathing clinical trials.
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have non-small cell lung cancer that is stage IB through IIIB.
- Your cancer can be fully removed with curative (radical) surgery.
- You are able to do daily activities with only mild limits (ECOG 0–1) and expect to live more than 24 months.
- You have blood and tumor samples that can be collected before surgery and after surgery, and they must be complete/usable.
- You have not had other cancers in the last 5 years and you did not receive chemotherapy or other cancer treatment before surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special blood test to look for tiny traces of lung cancer after surgery. It aims to find “minimal residual disease,” meaning cancer cells that may still be hiding after your tumor is removed.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
This trial tests whether a simple blood test (ctDNA) can help doctors decide if you need radiation therapy after lung cancer surgery. The goal is to tailor your treatment to your individual risk, possibly avoiding extra radiation if you don't need it.
This trial uses a blood test to look for tiny bits of cancer DNA after treatment. It may help find early signs that lung cancer has come back, so doctors can act sooner.
This study looks for tiny traces of cancer left in the body after treatment and surgery. It may help doctors understand if the cancer could come back, so it can be caught and treated earlier.
This study looks at tiny particles from the body (including from lung samples) to see if they can predict whether non-small cell lung cancer comes back after surgery. It may help doctors identify people at higher risk of recurrence sooner, so follow-up plans can be better tailored.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.